350 related articles for article (PubMed ID: 28100616)
1. The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity.
Wang Y; Pan Q; Ding S; Wang Z; Yu J; Finzi A; Liu SL; Liang C
J Virol; 2017 Apr; 91(7):. PubMed ID: 28100616
[TBL] [Abstract][Full Text] [Related]
2. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
[TBL] [Abstract][Full Text] [Related]
3. Functional Mapping of Regions Involved in the Negative Imprinting of Virion Particle Infectivity and in Target Cell Protection by Interferon-Induced Transmembrane Protein 3 against HIV-1.
Appourchaux R; Delpeuch M; Zhong L; Burlaud-Gaillard J; Tartour K; Savidis G; Brass A; Etienne L; Roingeard P; Cimarelli A
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355696
[TBL] [Abstract][Full Text] [Related]
4. Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection.
Beitari S; Pan Q; Finzi A; Liang C
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493821
[TBL] [Abstract][Full Text] [Related]
5. The Inhibition of HIV-1 Entry Imposed by Interferon Inducible Transmembrane Proteins Is Independent of Co-Receptor Usage.
Yu J; Liu SL
Viruses; 2018 Aug; 10(8):. PubMed ID: 30087232
[TBL] [Abstract][Full Text] [Related]
6. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.
Yu J; Li M; Wilkins J; Ding S; Swartz TH; Esposito AM; Zheng YM; Freed EO; Liang C; Chen BK; Liu SL
Cell Rep; 2015 Oct; 13(1):145-156. PubMed ID: 26387945
[TBL] [Abstract][Full Text] [Related]
7. IFITM1 and IFITM3 Proteins Inhibit the Infectivity of Progeny HIV-1 without Disrupting Envelope Glycoprotein Clusters.
Verma S; Chen YC; Marin M; Gillespie SE; Melikyan GB
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140631
[TBL] [Abstract][Full Text] [Related]
8. Escape of HIV-1 envelope glycoprotein from the restriction of infection by IFITM3.
Drouin A; Migraine J; Durand MA; Moreau A; Burlaud-Gaillard J; Beretta M; Roingeard P; Bouvin-Pley M; Braibant M
J Virol; 2021 Mar; 95(5):. PubMed ID: 33298540
[TBL] [Abstract][Full Text] [Related]
9. Functional Heterogeneity of Mammalian IFITM Proteins against HIV-1.
Marziali F; Delpeuch M; Kumar A; Appourchaux R; Dufloo J; Tartour K; Etienne L; Cimarelli A
J Virol; 2021 Aug; 95(18):e0043921. PubMed ID: 34160255
[TBL] [Abstract][Full Text] [Related]
10. Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction.
Foster TL; Wilson H; Iyer SS; Coss K; Doores K; Smith S; Kellam P; Finzi A; Borrow P; Hahn BH; Neil SJD
Cell Host Microbe; 2016 Oct; 20(4):429-442. PubMed ID: 27640936
[TBL] [Abstract][Full Text] [Related]
11. Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV.
Wilkins J; Zheng YM; Yu J; Liang C; Liu SL
PLoS One; 2016; 11(6):e0156739. PubMed ID: 27257969
[TBL] [Abstract][Full Text] [Related]
12. Effect of HIV-1 Env on SERINC5 Antagonism.
Beitari S; Ding S; Pan Q; Finzi A; Liang C
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928004
[TBL] [Abstract][Full Text] [Related]
13. Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.
Zhao X; Sehgal M; Hou Z; Cheng J; Shu S; Wu S; Guo F; Le Marchand SJ; Lin H; Chang J; Guo JT
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263263
[TBL] [Abstract][Full Text] [Related]
14. Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins.
Wrensch F; Hoffmann M; Gärtner S; Nehlmeier I; Winkler M; Pöhlmann S
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807233
[TBL] [Abstract][Full Text] [Related]
15. Duck Interferon-Inducible Transmembrane Protein 3 Mediates Restriction of Influenza Viruses.
Blyth GA; Chan WF; Webster RG; Magor KE
J Virol; 2016 Jan; 90(1):103-16. PubMed ID: 26468537
[TBL] [Abstract][Full Text] [Related]
16. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
17. Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules.
Cosma A; Blanc D; Braun J; Quillent C; Barassi C; Moog C; Klasen S; Spire B; Scarlatti G; Pesenti E; Siccardi AG; Beretta A
AIDS; 1999 Oct; 13(15):2033-42. PubMed ID: 10546855
[TBL] [Abstract][Full Text] [Related]
18. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
[TBL] [Abstract][Full Text] [Related]
19. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.
Tartour K; Nguyen XN; Appourchaux R; Assil S; Barateau V; Bloyet LM; Burlaud Gaillard J; Confort MP; Escudero-Perez B; Gruffat H; Hong SS; Moroso M; Reynard O; Reynard S; Decembre E; Ftaich N; Rossi A; Wu N; Arnaud F; Baize S; Dreux M; Gerlier D; Paranhos-Baccala G; Volchkov V; Roingeard P; Cimarelli A
PLoS Pathog; 2017 Sep; 13(9):e1006610. PubMed ID: 28957419
[TBL] [Abstract][Full Text] [Related]
20. Macaque interferon-induced transmembrane proteins limit replication of SHIV strains in an Envelope-dependent manner.
Sharma A; McLaughlin RN; Basom RS; Kikawa C; OhAinle M; Yount JS; Emerman M; Overbaugh J
PLoS Pathog; 2019 Jul; 15(7):e1007925. PubMed ID: 31260493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
